Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) ...

This leadership vacuum follows another significant departure at the FDA. Peter Marks, former head of the Center for Biologics Evaluation and Research who worked closely with Verdun on establishing new ...